Dry blend tablet coating and encapsulation

Published: 26-Mar-2014
Manufacturing Drug Delivery Pharmaceutical Dosage Forms


Alkermes Contract Pharma Services, a division of Alkermes Pharma Ireland Ltd, has significant experience in dry blend tableting and encapsulation processes to provide you with expert solutions to fulfill your specific manufacturing needs.

With more than 40 years of experience manufacturing for global markets at our dedicated site in Ireland, our key focus is to make quality medicines on time, every time for our partners.

With our robust process development approach, as well as reliable process scale-up to pilot and commercial scales, we consistently provide reliable and high-quality commercial manufacturing.

Download the full Capabilities and Expertise Fact Sheet.

  • Companies:
  • Alkermes Contract Pharma Services
See more

You may also like

Manufacturing

Fluid bed Wurster bead-coating, layering and encapsulation

Read more
In-house fluid bed coating, layering and encapsulation expertise, from pilot to full scale, allows for a successful tech-transfer process into commercial production

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    How CDMOs can set a new gold standard when it comes to going green Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards positive change, reports Tim Lowery, President of JSR Life Sciences and CEO, KBI Biopharma
  3. Mastering modified-release performance: excipient considerations Imagine a world where enhanced therapeutic efficacy, improved patient compliance and reduced adverse effects are tangible outcomes — even for drugs with short pharmacokinetic (PK) half-lives or narrow therapeutic indices. This is becoming a reality with modified-release (MR) oral delivery systems such as hydrophilic matrix tablets
  4. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

Fluid bed Wurster bead-coating, layering and encapsulation

In-house fluid bed coating, layering and encapsulation expertise, from pilot to full scale, allows for a successful tech-transfer process into commercial production
Manufacturing

Fluid bed top-spray granulation, blending, tableting and coating

In-house spray granulation and compression and coating expertise, from pilot to full commercial scale, allows for a successful tech-transfer process into commercial production
Manufacturing

Joint risk assessment during technical transfer - case study

A framework for donor and recipient companies to jointly analyse and document the technical and business risks associated with a technical transfer
Manufacturing

Outsourcing in the pharma industry – experience, expertise and enthusiasm

Key success factors in fostering and maintaining a long-term strategic partnership
Manufacturing

Highly potent technical transfer and commercial manufacturing

Alkermes’ successful approach to commercial-scale final dosage manufacture of drug product containing highly potent API
Finance

Alkermes to merge with Elan Drug Technologies

To create CNS therapeutics specialist Alkermes plc
Drug Delivery

EC approves injectable drug using Elan’s NanoCrystal technology

Enables the formulation of poorly water-soluble compounds
Subscribe now